Enhertu meets main goal in phase 3 lung cancer trial

August 17, 2026 2:30 AM

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) said their cancer drug Enhertu (trastuzumab deruxtecan) met the primary endpoint in ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found